Septerna, Inc.

Septerna, Inc.

Biotechnology • Healthcare • South San Francisco, CA, United States • SEPN (NGM)

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. The company also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

650 338 3533 250 East Grand Avenue, South San Francisco, CA 94080, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Septerna stock surges after Wells Fargo upgrade - Investing.com
Investing.com • Nov 14
Septerna's Novo Partnership Begins To Transform The Story (NASDAQ:SEPN) - Seeking Alpha
Seeking Alpha • Nov 25
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength? - Yahoo Finance
Yahoo Finance • Oct 9
Septerna joins a $2.2B obesity deal with Novo - BioWorld MedTech
BioWorld MedTech • May 14
$SEPN stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
Quiver Quantitative • Nov 24

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Septerna, Inc. had layoffs?
No layoff events have been recorded for Septerna, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Septerna, Inc. have?
Septerna, Inc. has approximately 75 employees.
What industry is Septerna, Inc. in?
Septerna, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Septerna, Inc. a publicly traded company?
Yes, Septerna, Inc. is publicly traded under the ticker symbol SEPN on the NGM. The company has a market capitalization of approximately $1.28 billion.
Where is Septerna, Inc. headquartered?
Septerna, Inc. is headquartered in South San Francisco, CA, United States at 250 East Grand Avenue, South San Francisco, CA 94080, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.